Top Markets
Coin of the day
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
株式のランク #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
株価
$4.06
最終同期: 2024-02-23
時価総額
$145.61M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Theseus Pharmaceuticals, Inc. (THRX)

カテゴリー

Theseus Pharmaceuticals, Inc.(THRX)の利益
2026 時点の利益 TTM: 0
Theseus Pharmaceuticals, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Theseus Pharmaceuticals, Inc. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH